Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

Implementing a standard internal telephone number 2222 for cardiac arrest calls in all hospitals in Europe.

Whitaker DK, Nolan JP, Castrén M, Abela C, Goldik Z.

Resuscitation. 2017 Jun;115:A14-A15. doi: 10.1016/j.resuscitation.2017.03.025. Epub 2017 Mar 22. No abstract available.

PMID:
28341349
2.

The European Board of Anaesthesiology recommendations for safe medication practice: First update.

Whitaker D, Brattebø G, Trenkler S, Vanags I, Petrini F, Aykac Z, Longrois D, Loer SA, Gaszynski T, Sipylaite J, Copaciu E, Cerny V, Akeson J, Mellin-Olsen J, Abela C, Stecher A, Kozek-Langenecker S, Rätsep I; European Section and Board of Anaesthesiology of the UEMS.

Eur J Anaesthesiol. 2017 Jan;34(1):4-7.

PMID:
27548778
3.

Prespecified dose-response analysis for A Very Early Rehabilitation Trial (AVERT).

Bernhardt J, Churilov L, Ellery F, Collier J, Chamberlain J, Langhorne P, Lindley RI, Moodie M, Dewey H, Thrift AG, Donnan G; AVERT Collaboration Group.

Neurology. 2016 Jun 7;86(23):2138-45. doi: 10.1212/WNL.0000000000002459. Epub 2016 Feb 17. Erratum in: Neurology. 2017 Jul 4;89(1):107.

4.

Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma.

Clement SC, Schoot RA, Slater O, Chisholm JC, Abela C, Balm AJ, van den Brekel MW, Breunis WB, Chang YC, Davila Fajardo R, Dunaway D, Gajdosova E, Gaze MN, Gupta S, Hartley B, Kremer LC, van Lennep M, Levitt GA, Mandeville HC, Pieters BR, Saeed P, Smeele LE, Strackee SD, Ronckers CM, Caron HN, van Santen HM, Merks JH.

Eur J Cancer. 2016 Feb;54:1-10. doi: 10.1016/j.ejca.2015.10.064. Epub 2015 Dec 17.

PMID:
26707591
5.

AVERT2 (a very early rehabilitation trial, a very effective reproductive trigger): retrospective observational analysis of the number of babies born to trial staff.

Bernhardt J, Lindley RI, Lalor E, Ellery F, Chamberlain J, Van Holsteyn J, Collier JM, Dewey HM, Parsons B, Moodie M, Lennon S, Donnan GA, Thrift AG, Churilov L, Langhorne P; AVERT Collaboration Group.

BMJ. 2015 Dec 11;351:h6432. doi: 10.1136/bmj.h6432.

6.

Exploring threats to generalisability in a large international rehabilitation trial (AVERT).

Bernhardt J, Raffelt A, Churilov L, Lindley RI, Speare S, Ancliffe J, Katijjahbe MA, Hameed S, Lennon S, McRae A, Tan D, Quiney J, Williamson HC, Collier J, Dewey HM, Donnan GA, Langhorne P, Thrift AG; AVERT Trialists’ Collaboration.

BMJ Open. 2015 Aug 17;5(8):e008378. doi: 10.1136/bmjopen-2015-008378.

7.

Painful exostosis of the external occipital protuberance.

Marshall RC, Abela C, Eccles S.

J Plast Reconstr Aesthet Surg. 2015 Nov;68(11):e174-6. doi: 10.1016/j.bjps.2015.06.013. Epub 2015 Jun 28. No abstract available.

PMID:
26261091
8.

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.

Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R; ENCORE1 Study Group.

Clin Pharmacol Ther. 2015 Oct;98(4):406-16. doi: 10.1002/cpt.156. Epub 2015 Jul 14.

9.

Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment.

Schoot RA, Slater O, Ronckers CM, Zwinderman AH, Balm AJ, Hartley B, van den Brekel MW, Gupta S, Saeed P, Gajdosova E, Pieters BR, Gaze MN, Mandeville HC, Fajardo RD, Chang YC, Gains JE, Strackee SD, Dunaway D, Abela C, Mason C, Smeele LE, Chisholm JC, Levitt GA, Kremer LC, Grootenhuis MA, Maurice-Stam H, Stiller CA, Hammond P, Caron HN, Merks JH.

Eur J Cancer. 2015 Jul;51(11):1424-34. doi: 10.1016/j.ejca.2015.02.010. Epub 2015 May 18.

PMID:
25998323
10.

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.

ENCORE1 Study Group, Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S, Mohapi L, Crabtree-Ramirez B, Jessen H, Kumar S, Winston A, Lee MP, Belloso W, Cooper DA, Emery S.

Lancet Infect Dis. 2015 Jul;15(7):793-802. doi: 10.1016/S1473-3099(15)70060-5. Epub 2015 Apr 12. Erratum in: Lancet Infect Dis. 2015 Jul;15(7):761.

PMID:
25877963
11.

Hypertelorism correction with facial bipartition and box osteotomy: does soft tissue translation correlate with bony movement?

Breakey W, Abela C, Evans R, Jeelani O, Britto J, Hayward R, Dunaway D.

J Craniofac Surg. 2015 Jan;26(1):196-200. doi: 10.1097/SCS.0000000000001237.

PMID:
25469891
12.

Frontofacial surgery in children and adolescents: techniques, indications, outcomes.

Britto JA, Greig A, Abela C, Hearst D, Dunaway DJ, Evans RD.

Semin Plast Surg. 2014 Aug;28(3):121-9. doi: 10.1055/s-0034-1384807.

13.

Toxic epidermal necrolysis (TEN): the Chelsea and Westminster Hospital wound management algorithm.

Abela C, Hartmann CE, De Leo A, de Sica Chapman A, Shah H, Jawad M, Bunker CB, Williams GJ, Leon-Villapalos J.

J Plast Reconstr Aesthet Surg. 2014 Aug;67(8):1026-32. doi: 10.1016/j.bjps.2014.04.003. Epub 2014 May 9.

PMID:
24860933
14.

HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.

Martin A, Moore CL, Mallon PW, Hoy JF, Emery S, Belloso WH, Phanuphak P, Ferret S, Cooper DA, Boyd MA; Second-Line Study Team.

PLoS One. 2013 Oct 30;8(10):e77138. doi: 10.1371/journal.pone.0077138. eCollection 2013.

15.

Prospective randomized controlled trial: fibrin sealant reduces split skin graft donor-site pain.

Healy C, Greig AV, Murphy AD, Powell C, Pinder RJ, Saour S, Abela C, Knight W, Geh JL.

Plast Reconstr Surg. 2013 Jul;132(1):139e-46e. doi: 10.1097/PRS.0b013e318299c6f4.

PMID:
23806933
16.

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.

SECOND-LINE Study Group, Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A, Kerr S, Sohn AH, Teppler H, Van de Steen O, Molina JM, Emery S, Cooper DA.

Lancet. 2013 Jun 15;381(9883):2091-9. doi: 10.1016/S0140-6736(13)61164-2.

PMID:
23769235
17.

Correcting the typical Apert face: combining bipartition with monobloc distraction.

Greig AV, Britto JA, Abela C, Witherow H, Richards R, Evans RD, Jeelani NU, Hayward RD, Dunaway DJ.

Plast Reconstr Surg. 2013 Feb;131(2):219e-230e. doi: 10.1097/PRS.0b013e3182778882.

PMID:
23358017
18.

Complications of frontofacial advancement.

Dunaway DJ, Britto JA, Abela C, Evans RD, Jeelani NU.

Childs Nerv Syst. 2012 Sep;28(9):1571-6. doi: 10.1007/s00381-012-1804-y. Epub 2012 Aug 8. Review.

PMID:
22872275
19.

Third WHO Global Consultation on Organ Donation and Transplantation: striving to achieve self-sufficiency, March 23–25, 2010, Madrid, Spain.

WHO; Transplantation Society (TTS); Organizatión Nacional de Transplantes (ONT).

Transplantation. 2011 Jun 15;91 Suppl 11:S27-8. doi: 10.1097/TP.0b013e3182190b29. No abstract available.

PMID:
21633280
20.

A multidisciplinary approach to post-bariatric plastic surgery.

Abela C, Stevens T, Reddy M, Soldin M.

Int J Surg. 2011;9(1):29-35. doi: 10.1016/j.ijsu.2010.10.002. Epub 2010 Nov 12. Review.

Supplemental Content

Loading ...
Support Center